Lv21
140 积分 2024-06-25 加入
Antibody-drug conjugates for non-small cell lung cancer: Advantages and challenges in clinical translation
2小时前
待确认
Claudin 18.2 as a novel therapeutic target
4天前
已完结
DNA Damage Repair Inhibitors—Combination Therapies
6天前
已完结
Targeting DNA damage response pathways in cancer
8天前
已完结
Depth in biotech and pharma mergers and acquisitions. How much should you integrate? A multi-case analysis
1个月前
已完结
Non-coding RNAs in disease: from mechanisms to therapeutics
2个月前
已完结
Exploring the therapeutic potential of ADC combination for triple-negative breast cancer
2个月前
已完结
Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial
4个月前
已完结
Claudin18.2-specific CAR T cells in gastrointestinal cancers: phase 1 trial final results
4个月前
已完结
Cancer profiles in China and comparisons with the USA: a comprehensive analysis in the incidence, mortality, survival, staging, and attribution to risk factors
4个月前
已完结
皖公网安备34019202002308
